✦ LIBER ✦

85 The diagnostic value of cell free DNA levels in prostate cancer and a reminder on the importance of sample selection

✍ Scribed by J. Boddy; S. Gal; A. Harris; J. Wainscoat; P. Malone

Book ID: 118645301
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 202 KB
Volume: 3
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(04)90087-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A study on the levels of calmodulin and

A study on the levels of calmodulin and DNA in human lung cancer cells

✍ Liu, G-X; Sheng, H-F; Wu, S 📂 Article 📅 1996 🏛 Nature Publishing Group 🌐 English ⚖ 519 KB

A study on the levels of calmodulin and

A study on the levels of calmodulin and DNA in human lung cancer cells

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 148 KB

The effect of percentage free prostate-s

The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels

✍ Alexandre E. Pelzer; Hubert Volgger; Jasmin Bektic; Andreas P. Berger; Peter Reh 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

THE EFFECT OF PROSTATE VOLUME, AGE, TOTA

THE EFFECT OF PROSTATE VOLUME, AGE, TOTAL PROSTATE SPECIFIC ANTIGEN LEVEL AND ACUTE INFLAMMATION ON THE PERCENTAGE OF FREE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITHOUT CLINICALLY DETECTABLE PROSTATE CANCER

✍ ORNSTEIN, DAVID K.; SMITH, DEBORAH S.; HUMPHREY, PETER A.; CATALONA, WILLIAM J. 📂 Article 📅 1998 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 472 KB

PROSTATE CANCER DETECTION IN THE PROSTAT

PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESS

✍ RAAIJMAKERS, RENÉ; BLIJENBERG, BERT G.; FINLAY, JUDITH A.; RITTENHOUSE, HARRY G. 📂 Article 📅 2004 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 94 KB

OP78 EGFR mutations based on circulating

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB